Merck Serono and Apitope Technology Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis; Apitope Eligible to Receive up to EUR 154 Million
1/13/2009 6:46:41 AM
More...
|
Apitope Technology's ATX-MS-1467 Completes Dosing Stage in a Phase I/IIa Trial in Multiple Sclerosis Patients
11/5/2007 12:39:13 PM
More...
|